Last reviewed · How we verify

Corticotropin-Releasing Hormone

Centre for Addiction and Mental Health · Phase 2 active Small molecule

Corticotropin-Releasing Hormone stimulates the release of adrenocorticotropic hormone (ACTH) from the pituitary gland, which in turn increases cortisol production.

Corticotropin-Releasing Hormone stimulates the release of adrenocorticotropic hormone (ACTH) from the pituitary gland, which in turn increases cortisol production. Used for Treatment of major depressive disorder.

At a glance

Generic nameCorticotropin-Releasing Hormone
Also known ascorticorelin
SponsorCentre for Addiction and Mental Health
TargetCRHR1, CRHR2
ModalitySmall molecule
Therapeutic areaPsychiatry
PhasePhase 2

Mechanism of action

When CRH binds to its receptors in the anterior pituitary gland, it triggers a cascade that leads to the synthesis and secretion of ACTH. This hormone then acts on the adrenal cortex to produce and release cortisol, which plays a role in stress response and metabolism.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: